Where Avidity Biosciences Stands With Analysts
Portfolio Pulse from Benzinga Insights
Avidity Biosciences (NASDAQ:RNA) has seen varied analyst opinions over the past three months, with a total of 6 analysts offering ratings ranging from bullish to bearish. The recent ratings show a shift towards a more positive outlook, with 5 bullish and 1 somewhat bullish ratings. The 12-month price targets suggest an average target of $36.83, indicating a significant upward trend from the previous average of $23.00. Despite challenges in revenue growth and asset utilization, Avidity Biosciences's market capitalization and net margin indicate a strong market position and profitability.
April 11, 2024 | 12:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Avidity Biosciences has received increasingly positive analyst ratings, with a notable upward revision in the 12-month price target to $36.83 from $23.00, reflecting optimism about the company's future performance.
The positive shift in analyst sentiment, evidenced by the increase in bullish ratings and the significant upward revision in the 12-month price target, suggests a strong short-term bullish outlook for RNA. The company's strong market position, as indicated by its market capitalization and net margin, further supports this positive outlook, despite the challenges in revenue growth and asset utilization.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100